PE20231746A1 - Compuestos de union a cereblon, composiciones de estos y metodos de tratamiento con estos - Google Patents
Compuestos de union a cereblon, composiciones de estos y metodos de tratamiento con estosInfo
- Publication number
- PE20231746A1 PE20231746A1 PE2022003029A PE2022003029A PE20231746A1 PE 20231746 A1 PE20231746 A1 PE 20231746A1 PE 2022003029 A PE2022003029 A PE 2022003029A PE 2022003029 A PE2022003029 A PE 2022003029A PE 20231746 A1 PE20231746 A1 PE 20231746A1
- Authority
- PE
- Peru
- Prior art keywords
- treatment
- compositions
- methods
- phenyl
- binding compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 title 1
- 102100032783 Protein cereblon Human genes 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 102000001307 androgen receptors Human genes 0.000 abstract 1
- 108010080146 androgen receptors Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- CNMOHEDUVVUVPP-UHFFFAOYSA-N piperidine-2,3-dione Chemical compound O=C1CCCNC1=O CNMOHEDUVVUVPP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063043555P | 2020-06-24 | 2020-06-24 | |
| PCT/US2021/038618 WO2021262810A1 (en) | 2020-06-24 | 2021-06-23 | Cereblon binding compounds, compositions thereof, and methods of treatment therewith |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231746A1 true PE20231746A1 (es) | 2023-11-06 |
Family
ID=79032408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022003029A PE20231746A1 (es) | 2020-06-24 | 2021-06-23 | Compuestos de union a cereblon, composiciones de estos y metodos de tratamiento con estos |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11634407B2 (https=) |
| EP (1) | EP4171566A4 (https=) |
| JP (2) | JP7781792B2 (https=) |
| KR (1) | KR20230027066A (https=) |
| CN (2) | CN120441548A (https=) |
| AR (1) | AR122723A1 (https=) |
| AU (1) | AU2021296833A1 (https=) |
| BR (1) | BR112022025933A2 (https=) |
| CA (1) | CA3182325A1 (https=) |
| CL (1) | CL2022003719A1 (https=) |
| CO (1) | CO2022018653A2 (https=) |
| IL (1) | IL299256A (https=) |
| MX (1) | MX2022015757A (https=) |
| PE (1) | PE20231746A1 (https=) |
| SA (1) | SA522441857B1 (https=) |
| TW (1) | TW202216680A (https=) |
| WO (1) | WO2021262810A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020405129A1 (en) | 2019-12-19 | 2022-06-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| CR20220630A (es) | 2020-05-09 | 2023-01-23 | Arvinas Operations Inc | Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo |
| JP7778095B2 (ja) | 2020-06-24 | 2025-12-01 | セルジーン コーポレーション | セレブロン結合化合物、その組成物及びそれによる治療方法 |
| KR20230027214A (ko) | 2020-06-24 | 2023-02-27 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
| KR20230027066A (ko) | 2020-06-24 | 2023-02-27 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
| CN117561249A (zh) * | 2021-06-25 | 2024-02-13 | 细胞基因公司 | Cereblon结合化合物、其组合物及其用于治疗的方法 |
| EP4584259A1 (en) | 2022-09-09 | 2025-07-16 | Innovo Therapeutics, Inc. | Ck1alpha and dual ck1alpha / gspt1 degrading compounds |
| WO2025063888A1 (en) | 2023-09-19 | 2025-03-27 | Kancure Pte. Ltd. | Survivin-targeted compounds |
| TW202535392A (zh) | 2023-12-08 | 2025-09-16 | 美商亞文納營運公司 | 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮 |
| WO2025179161A1 (en) | 2024-02-21 | 2025-08-28 | Innovo Therapeutics, Inc. | Protein degrading compounds |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101032483B (zh) * | 2006-03-09 | 2011-05-04 | 陈德桂 | 调节雄激素受体活性的乙内酰脲衍生物及其应用 |
| JP6817962B2 (ja) * | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| CN109641874A (zh) * | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| CN110023297A (zh) * | 2016-07-08 | 2019-07-16 | 詹森药业有限公司 | 作为雄性激素受体拮抗剂的取代的乙内酰脲和硫代己内酰脲衍生物 |
| CN110769822A (zh) * | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| WO2020051260A1 (en) * | 2018-09-05 | 2020-03-12 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (sard) ligands and methods of use thereof |
| CN113473987B (zh) | 2018-12-19 | 2024-09-03 | 细胞基因公司 | 被取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物、其组合物和使用其的治疗方法 |
| CN113453681B (zh) | 2018-12-19 | 2024-10-11 | 细胞基因公司 | 经取代的3-((3-氨基苯基)氨基)哌啶-2，6-二酮化合物、其组合物及使用它们的治疗方法 |
| JP7778095B2 (ja) | 2020-06-24 | 2025-12-01 | セルジーン コーポレーション | セレブロン結合化合物、その組成物及びそれによる治療方法 |
| KR20230027214A (ko) | 2020-06-24 | 2023-02-27 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
| KR20230027066A (ko) | 2020-06-24 | 2023-02-27 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
-
2021
- 2021-06-23 KR KR1020227044904A patent/KR20230027066A/ko active Pending
- 2021-06-23 PE PE2022003029A patent/PE20231746A1/es unknown
- 2021-06-23 CN CN202510574007.2A patent/CN120441548A/zh active Pending
- 2021-06-23 WO PCT/US2021/038618 patent/WO2021262810A1/en not_active Ceased
- 2021-06-23 CA CA3182325A patent/CA3182325A1/en active Pending
- 2021-06-23 TW TW110122923A patent/TW202216680A/zh unknown
- 2021-06-23 AU AU2021296833A patent/AU2021296833A1/en active Pending
- 2021-06-23 EP EP21827824.0A patent/EP4171566A4/en active Pending
- 2021-06-23 US US17/356,370 patent/US11634407B2/en active Active
- 2021-06-23 AR ARP210101735A patent/AR122723A1/es unknown
- 2021-06-23 JP JP2022580090A patent/JP7781792B2/ja active Active
- 2021-06-23 BR BR112022025933A patent/BR112022025933A2/pt unknown
- 2021-06-23 CN CN202180044295.0A patent/CN115835866B/zh active Active
- 2021-06-23 MX MX2022015757A patent/MX2022015757A/es unknown
- 2021-06-23 IL IL299256A patent/IL299256A/en unknown
-
2022
- 2022-12-22 CO CONC2022/0018653A patent/CO2022018653A2/es unknown
- 2022-12-22 CL CL2022003719A patent/CL2022003719A1/es unknown
- 2022-12-22 SA SA522441857A patent/SA522441857B1/ar unknown
-
2023
- 2023-03-16 US US18/122,496 patent/US12103920B2/en active Active
-
2024
- 2024-07-18 US US18/776,606 patent/US20250188056A1/en active Pending
-
2025
- 2025-11-26 JP JP2025203650A patent/JP2026035702A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AR122723A1 (es) | 2022-09-28 |
| US20250188056A1 (en) | 2025-06-12 |
| CA3182325A1 (en) | 2021-12-30 |
| EP4171566A4 (en) | 2024-07-24 |
| SA522441857B1 (ar) | 2024-07-21 |
| US20210403454A1 (en) | 2021-12-30 |
| US20230242509A1 (en) | 2023-08-03 |
| IL299256A (en) | 2023-02-01 |
| US11634407B2 (en) | 2023-04-25 |
| JP7781792B2 (ja) | 2025-12-08 |
| JP2026035702A (ja) | 2026-03-04 |
| WO2021262810A1 (en) | 2021-12-30 |
| CN115835866B (zh) | 2025-05-02 |
| KR20230027066A (ko) | 2023-02-27 |
| AU2021296833A1 (en) | 2023-01-19 |
| CL2022003719A1 (es) | 2023-05-12 |
| CN120441548A (zh) | 2025-08-08 |
| JP2023533203A (ja) | 2023-08-02 |
| MX2022015757A (es) | 2023-01-19 |
| US12103920B2 (en) | 2024-10-01 |
| EP4171566A1 (en) | 2023-05-03 |
| CN115835866A (zh) | 2023-03-21 |
| TW202216680A (zh) | 2022-05-01 |
| CO2022018653A2 (es) | 2023-03-27 |
| BR112022025933A2 (pt) | 2023-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20231746A1 (es) | Compuestos de union a cereblon, composiciones de estos y metodos de tratamiento con estos | |
| PE20221628A1 (es) | Compuestos inhibidores de rip1 y metodos para hacer y utilizar los mismos | |
| PE20211733A1 (es) | Amidas de pirrolidina sustituidas | |
| PE20070138A1 (es) | Compuestos heterociclicos como inhibidores de aspartil proteasas | |
| PE20220569A1 (es) | Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y metodos de tratamiento con dichos compuestos | |
| PE20090435A1 (es) | Inhibidores de tetrahidropiranocromeno de gamma secretasa | |
| NO20050741L (no) | Ny fremgangsmate for syntesen og ny krystallinsk form av agomelatin og farmasoytiske sammensetninger inneholdende den | |
| PE20141681A1 (es) | Inhibidores de btk | |
| PE20081894A1 (es) | Derivados de isoindolina 4'-o-sustituidos y composiciones que los comprenden y metodos para usarlos | |
| PE20090772A1 (es) | Derivados de bencimidazol | |
| PE20110367A1 (es) | DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2 | |
| PE20040960A1 (es) | Derivados de piperazina acilados como agonistas del receptor de melanocortina-4 | |
| PE20130009A1 (es) | Inhibidores de la replicacion del virus de la inmunodeficiencia humana | |
| PE20090890A1 (es) | Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c | |
| PE20011371A1 (es) | Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5 | |
| PE20090727A1 (es) | DERIVADOS DE AMIDA COMO INHIBIDORES DE NaV1.7 | |
| PE20091843A1 (es) | Inhibidores de catepsina c | |
| ECSP055615A (es) | Nuevos compuestos de amida de ácido carboxílico con efecto antagónico de la hcm, medicamentos que contienen estos compuestos y procedimientos para su preparación | |
| PE20051054A1 (es) | Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento | |
| PE20110150A1 (es) | Amidofenoxiindazoles como inhibidores de c-met | |
| PE20061357A1 (es) | COMPUESTOS DERIVADOS DE AMINOSULFONILO COMO INHIBIDORES DE LA 11-ß-HSD-1 | |
| PE20081753A1 (es) | Compuestos y composiciones como inhibidores de la proteasa activadora de canal | |
| PE20060401A1 (es) | Derivados de n-(2-bencil)-2-fenil-butanamidas y propanamidas como moduladores del receptor de androgeno | |
| PE20110433A1 (es) | Antagonistas de la via hedgehog de ftalazina disustituida | |
| PE20080889A1 (es) | Aminometil-4-imidazoles |